Pfizer Corporation

Simone Sciabola

Patrick Robert Verhoest

Thomas Allen Chappie

Nandini Chaturbhai Patel

Christopher John Helal

Erik Alphie LaChapelle

Travis T Wager

Matthew Merrill Hayward

Joseph Michael Young

Jamison Bryce Tuttle

Jaclyn Louise Henderson

Bethany Lyn Kormos

Ramalakshmi Yegna Chandrasekaran

Joseph Walter Tucker

Neelu Kaila

Tarek A Samad

Karen Jean Coffman

Michael L Vazquez

Matthew Richard Reese

Mihir D Parikh

James M Duerr

Erik Alphie Lachapelle

Travis T Wagner

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R, R, R, R, R, Rand n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

Tricyclic compounds and their use as phosphodiesterase inhibitors

The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression. 

6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands

Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.

Pyrrolo[2,3-d]pyrimidine derivatives

The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds. 

6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, R, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

Imidazopyridazine compounds

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

The present invention is directed to pyrazolopyrimine compounds or pharmaceutically acceptable salts which are inhibitors of PDE4 isozymes, especially with a binding affinity for PDE4B isoform, and compositions thereof.

Pyrazolopyrimidine compounds

Growing community of inventors

Cambridge, MA, United States of America

Simone Sciabola